Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan‐Tumor
Cancer Innovation · 2026-04 · 5 (2)
DOI: 10.1002/cai2.70060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Innovation, online erschienen am 21.04.2026. Verfasst von Zhe Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Xijing Hospital and School of Basic Medicine Fourth Military Medical University Xi'an China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Human epidermal growth factor receptor 2 (HER2) is a key biomarker and therapeutic target in several malignancies, including breast, gastric, and other solid tumors. Recent advancements in cancer molecular profiling and the Food and Drug Administration's approval of trastuzumab deruxtecan for HER2‐positive pan‐tumor indications have highlighted the broader relevance of HER2 alterations across diverse cancers. However, the lack of standardized guidelines for HER2 testing in a pan‐tumor context creates variability in clinical practice, hindering the optimal implementation of HER2‐targeted therapies beyond traditional indications. To address this gap, a multidisciplinary panel of Chinese experts has developed a consensus providing comprehensive recommendations on diagnostic strategies, testing methodologies, and clinical applications of HER2 overexpression detection. By establishing a unified framework for HER2 overexpression assessment, this consensus aims to enhance the precision of HER2 testing, optimize patient selection for targeted therapies, and improve clinical outcomes across a wide spectrum of HER2 overexpression malignancies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Xijing Hospital and School of Basic Medicine Fourth Military Medical University Xi'an China.
- Department of Gastrointestinal Surgery Peking University International Hospital Beijing China.
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China.
- Department of Medical Oncology and Radiation Sickness Peking University Third Hospital Beijing China.
- Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Guangzhou China.
- Department of Pathology The First Affiliated Hospital of Anhui Medical University Hefei China.
ORCID-Profile: Jianming Ying
Zitieren
APA
Wang, Z., Chen, L., Rao, W., Cao, B., Cai, M., Fan, X., Ji, Y., Li, Y., Song, Y., Sun, Y., Sun, Y., Wu, C., Xia, Q., Xi, Y., Xue, L., Yin, R., Liang, H., & Ying, J. (2026). Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan‐Tumor. Cancer Innovation, 5(2). https://doi.org/10.1002/cai2.70060
Vancouver
Wang Z, Chen L, Rao W, Cao B, Cai M, Fan X, et al. Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan‐Tumor. Cancer Innovation. 2026;5(2). doi:10.1002/cai2.70060
BibTeX
@article{Wang2026,
author = {Wang, Zhe and Chen, Lin and Rao, Wei and Cao, Baoshan and Cai, Muyan and Fan, Xiangshan and Ji, Yuan and Li, Yuan and Song, Yan and Sun, Yan and Sun, Yu and Wu, Chunyan and Xia, Qingxin and Xi, Yanfeng and Xue, Liyan and Yin, Rutie and Liang, Han and Ying, Jianming},
title = {Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan‐Tumor},
journal = {Cancer Innovation},
year = {2026},
volume = {5},
number = {2},
doi = {10.1002/cai2.70060}
}
EUVIMED